Search
Influenza A virus A/Delaware/39/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15708ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15712ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15714ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15788ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Indium In-111 imciromab pentetate
go.drugbank.com/drugs/DB09339ApprovedWithdrawnIndium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigational[A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.
DG051
go.drugbank.com/drugs/DB05177ExperimentalDG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.
Pirbuterol
go.drugbank.com/drugs/DB01291ApprovedWithdrawnenzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). … The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the
Categories: Agents to Treat Airway DiseaseIndigotindisulfonic acid
go.drugbank.com/drugs/DB11577ApprovedInvestigational[A251405] Indigotindisulfonic acid is used in clinical medicine to determine patency of the urinary collecting system, and to assist in specific surgical procedures such as cystourethroscopy. … [A32490,A32491,A32492] In 2022, the FDA approved the intravenous use of indigotindisulfonate sodium to aid in visualizing ureter integrity in cystoscopic assessments.[L42600]
CX-051869
go.drugbank.com/drugs/DB31656ApprovedCX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1. It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.